Company ProfileCompany Profile
We will continue to take on the challenge.
A quarter of a century has passed since JTEC Corporation was founded in December 1993. The path we have taken has not been a smooth one.
During this time, we have consistently challenged ourselves faster than anyone else, without fear of failure, and pursued results under our management philosophy of "contributing to society at large by creating products with unique, one-of-a-kind technologies.
Currently, we are engaged in the optical business centering on X-ray focusing mirrors for synchrotron radiation, the results of research conducted by Osaka University and RIKEN, which we have successfully put to practical use, and the life science business centering on various automatic cell culture devices, which we have developed based on our unique cell culture technology cultivated since the company's foundation. We have concentrated our management resources on two core businesses: science and equipment development, and have promoted the expansion of our business scale.
The SPring-8 large synchrotron radiation facility and the SACLA X-ray free electron laser facility, both located in Hyogo Prefecture, have been used to conduct basic research in various fields such as medicine, life science, and material science. Our X-ray mirrors for synchrotron radiation have been installed in such large synchrotron radiation facilities and X-ray free electron laser facilities in Japan and overseas, and are used for product development in many industrial fields. The company has received high acclaim and was selected by the Ministry of Economy, Trade and Industry (METI) as one of the "Top 100 Global Niche Companies for 2020" in the materials/chemicals category.
The X-ray mirror has achieved atomic-level surface profile accuracy in the nanometer range, and we are actively pursuing joint development with leading companies in various fields in order to expand our products into industrial fields other than synchrotron radiation facilities, such as semiconductors, space, and medical fields. We will continue to boldly take on new challenges in pursuit of competitive advantage.
In addition to EEM, a unique atomic-level nanofabrication technology that realizes this X-ray mirror, and RADSI/MSI, a unique nano-measurement technology based on stitching using an interferometer, we are also developing new nano-fabrication technologies such as CARE using catalytic action and PCVM using high-pressure plasma, as well as new nano-measurement technologies such as the RADSI/MSI technology, and the RADSI/MSI technology. We are promoting the practical application and development of new nano measurement technologies such as CMM, and applying our original nano processing technologies to high-precision mask substrates for next-generation semiconductors, which require nanometer-accurate thickness distribution, and crystal wafers for high-precision crystal oscillators, which are in increasing demand due to 5G commercial services and IoT applications. We are developing various types of nanofabrication equipment.
On the other hand, in the area of automated cell culture systems, we have successfully developed a 3D cell culture system in the field of regenerative medicine, for which demand is expected to grow in the future, based on our proprietary 3D floating culture technology, Cell Float®, for which we have conducted research and development for many years in collaboration with the National Institute of Advanced Industrial Science and Technology (AIST). We will continue our efforts to contribute to society as soon as possible by conducting clinical research in collaboration with medical schools of Osaka University and Yokohama City University and other institutions.
In the field of drug discovery, we are focusing on the development of general-purpose products as well as the manufacture and sale of various custom-made automated cell devices, which we have been promoting since our establishment. In particular, we are promoting the development of technology and products related to iPS cells, as well as the development of products for the cultivation of organoids (also known as "mini-organs"), which are expected to be used as a discovery tool for next-generation therapeutic drugs and are useful in the treatment of new types of coronavirus infection.
In the field of life science, for example, various culture technologies have been proposed for various types of culture equipment, and new technologies and services are being created one after another. We will continue to grow in response to these changes and aim to become the leading company in cell culture-related equipment.
Last of all, we are pleased to announce that we have moved our stock listing from the Mothers Market to the First Section of the Tokyo Stock Exchange. We will take this opportunity to challenge new fields, improve our technical capabilities, and build a new pillar of business to further expand our operations and increase our corporate value.
President of JTEC CorporationTakashi Tsumura